Related Experiment Videos
[The effect of antibody against vascular endothelial growth factor (VEGF) on tumor metastasis]
Objective:
To study whether manipulation of angiogenesis with antibody against vascular endothelial growth factor (VEGF) may interrupt the tumor growth and metastasis.
Methods:
IV TA2MA 891 is a murine spontaneous breast cancer with high rate of metastasis in lung in (TA2x615) F1 mice, and it was chosen as an animal model in this study because of the high expression of VEGF in primary tumor as well as in lung metastatic tumor. The mice were injected with anti-VEGF polyclonal antibody at a dose of 200 micrograms/mouse/day from day 9 to 23 following s.c. tumor inoculation and sacrificed on day 26.
Results:
The growth of primary tumor was inhibited by 44.0% and the number and size of metastatic foci in the lungs were inhibited by 73.0% and 83.7% respectively.
Conclusion:
The antibody against human VEGF may be a potentially effective antimetastasis agent for the treatment of patients with lung metastasis.
Insights
Targeting angiogenesis with an anti-vascular endothelial growth factor (VEGF) antibody significantly reduced primary tumor growth and lung metastasis in a mouse model. This antibody shows potential as an antimetastasis agent for lung metastasis treatment.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Context:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
- Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis and is often overexpressed in tumors.
- Targeting VEGF is a promising strategy for cancer therapy.
Purpose:
- To investigate the efficacy of an anti-VEGF antibody in inhibiting tumor growth and metastasis.
- To evaluate the anti-VEGF antibody's potential as an antimetastasis agent.
Summary:
- A murine breast cancer model (TA2MA 891) with high metastatic potential was used.
- Mice received an anti-VEGF polyclonal antibody, significantly inhibiting primary tumor growth (44.0%) and lung metastasis (73.0% in number, 83.7% in size).
- VEGF expression was high in both primary and metastatic tumors, supporting the target's relevance.
Impact:
- Anti-VEGF antibody therapy demonstrates significant potential in reducing tumor burden and preventing metastasis.
- This approach may offer a novel therapeutic strategy for patients with lung metastasis.
- Further research into anti-VEGF therapies could lead to improved cancer treatment outcomes.